Login to Your Account



Aimmune hits full PALISADE enrollment, closes $145M Nestlé investment

By Michael Fitzhugh
Staff Writer

Monday, November 28, 2016

Global enrollment is complete in the first of two pivotal trials that will back 2018 regulatory filings for the experimental oral peanut allergy treatment AR101, developed by Aimmune Therapeutics Inc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription